Showing results (1241-1250 of 3,716) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|August 5, 2004
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumorsSamir D Undevia, Nicholas J Vogelzang, Ann M Mauer, et al.Investigational New Drugs|August 5, 2004
Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinomaDevansu Tewari, Bradley J Monk, Mark Hunter, et al.Investigational New Drugs|August 5, 2004
Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: results of a phase II studyJosé Luis Firvida, Margarita Amenedo, Rubén Rodríguez, et al.Investigational New Drugs|November 1, 1993
Phase II trial of LY 186641 in advanced renal cancerM Mahjoubi, J Kattan, M Bonnay, et al.Investigational New Drugs|January 1, 1984
Evaluation of various cytostatic drugs as local immunotherapeutic agentsR J Scheper, A Vos, J de Groot, et al.Investigational New Drugs|January 1, 1994
Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I studyC F Pollera, A Ceribelli, M Crecco, et al.Investigational New Drugs|January 1, 1994
Phase II trial of intravenous melphalan in advanced colorectal carcinomaD F Moore, R Pazdur, J L AbbruzzeseInvestigational New Drugs|January 1, 1994
A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinomaJ Berlin, A C King, K Tutsch, et al.Investigational New Drugs|January 1, 1994
Phase II evaluation of merbarone in renal cell carcinomaR C Flanigan, J H Saiers, M Wolf, et al.Investigational New Drugs|January 1, 1994
Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancerD L Trump, J A Hathorn, L B Grochow, et al.Pageof 372